Text Size

Changes in ocular signs and symptoms in patients switching from bimatoprost-Timolol to tafluprost-Timolol eye drops: An open-label phase IV study

Bourne R.R.A., Kaarniranta K., Lorenz K., Traverso C.E., Vuorinen J., Ropo A.


  • 2019
  • BMJ Open
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Cambridge University Hospitals, Cambridge, United Kingdom; Vision and Eye Research Unit, Anglia Ruskin University, Cambridge, United Kingdom; Department of Ophthalmology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland; Department of Ophthalmology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany; Clinica Oculistica Di.N.O.G.M.I., Università di Genova, Ospedale Policlinico San Martino, Genova, Italy; 4Pharma Ltd, Turku, Finland; Global Medical Affairs, Santen Oy, Helsinki, Finland

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.


Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.


The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022